|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.115 USD | +3.68% |
|
+0.71% | -60.61% |
| 06-29 | Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark | CI |
| 06-29 | Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark | CI |
Company Valuation: Compass Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 309 | 633.5 | 198.8 | 199.5 | 955.1 | 367.4 | - | - |
| Change | - | 105.02% | -68.61% | 0.34% | 378.75% | -61.54% | - | - |
| Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 72.78 | 955.1 | 217.4 | 235.4 | 289.4 |
| Change | - | 105.02% | -68.61% | -63.39% | 1,212.3% | -77.24% | 8.28% | 22.94% |
| P/E | -2.42x | -13.6x | -4.73x | -4.03x | -12.8x | -4.68x | -4.39x | -14.2x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.4x | -0.44x | -0.8x | -1.23x | -0.67x | 0.2x |
| Capitalization / Revenue | - | - | - | 235x | - | -179x | 14.5x | 2.9x |
| EV / Revenue | - | - | - | 85.6x | - | -106x | 9.31x | 2.28x |
| EV / EBITDA | -3.8x | -15.5x | -4x | -1.3x | -13.2x | -2.48x | -2.48x | -3.2x |
| EV / EBIT | -3.77x | -15.2x | -3.95x | -1.29x | -13.1x | -2.52x | -2.54x | -9.29x |
| EV / FCF | -14.3x | - | - | -1.62x | -19.4x | -3.03x | -3.01x | -15x |
| FCF Yield | -6.98% | - | - | -61.7% | -5.15% | -33% | -33.2% | -6.68% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.31 | -0.37 | -0.33 | -0.36 | -0.42 | -0.436 | -0.4647 | -0.1433 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 0.85 | - | -2.057 | 25.27 | 126.9 |
| EBITDA 1 | -81.32 | -40.87 | -49.66 | -56.04 | -72.56 | -87.6 | -94.75 | -90.29 |
| EBIT 1 | -81.88 | -41.66 | -50.36 | -56.62 | -72.84 | -86.22 | -92.52 | -31.14 |
| Net income 1 | -82.18 | -39.22 | -42.49 | -49.38 | -66.49 | -82.44 | -89.57 | -28 |
| Net Debt 1 | - | - | - | -126.7 | - | -150 | -132 | -78 |
| Reference price 2 | 3.170 | 5.030 | 1.560 | 1.450 | 5.370 | 2.040 | 2.040 | 2.040 |
| Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | 177,862 | 180,088 | - | - |
| Announcement Date | 18/03/22 | 15/03/23 | 21/03/24 | 27/02/25 | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.68x | -105.67x | -2.48x | - | 367M | |
| 20.83x | 6.36x | 13.92x | 1.53% | 55.27B | |
| 32.72x | 8.17x | 25.61x | 0.05% | 54.15B | |
| -41.75x | 13.26x | -39.07x | -.--% | 23.11B | |
| -18.34x | 4.38x | -7.67x | -.--% | 23.22B | |
| 25.44x | 5.01x | 13.23x | -.--% | 20.33B | |
| 24.96x | 4.84x | 15.73x | -.--% | 17.91B | |
| -612.56x | 37.5x | -1557.05x | -.--% | 15.76B | |
| 45.31x | 18.35x | 47.24x | 0.08% | 15B | |
| 17.3x | 5.01x | 11.68x | -.--% | 13.82B | |
| Average | -51.08x | -0.28x | -147.89x | 0.18% | 23.89B | |
| Weighted average by Cap. | -26.12x | 9.57x | -92.27x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CMPX Stock
- Valuation Compass Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
